AbbVie takes over development of cystic fibrosis research program

26 October 2018

US biopharma firm AbbVie (NYSE: ABBV) will assume full development and commercial responsibility for its collaboration with Belgo-Dutch biotech Galapagos (Euronext: GLPG) to discover and develop new therapies to treat cystic fibrosis (CF).

AbbVie's research program aims to develop a best-in-class, triple-combination therapy for patients living with cystic fibrosis. Currently in early clinical development, the program consists of mechanistically distinct drug-candidates, termed "potentiators" and "correctors," which collectively increase the activity of the mutated copies of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that causes CF.

AbbVie will apply its expertise in medicinal chemistry and small-molecule drug discovery and development to produce promising candidates that will help change the standard of care for CF patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK